Making trials matter: pragmatic and explanatory trials and the problem of applicability by Treweek, Shaun & Zwarenstein, Merrick
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
Trials
Open Access Review
Making trials matter: pragmatic and explanatory trials and the 
problem of applicability
Shaun Treweek*1,2 and Merrick Zwarenstein3,4,5
Address: 1Division of Clinical and Population Sciences and Education, University of Dundee, Dundee, UK, 2Norwegian Knowledge Centre for the 
Health Services, Oslo, Norway, 3Centre for Health Services Sciences, Sunnybrook Research Institute, Sunnybrook   Health Sciences Centre, 
Toronto, Ontario, Canada, 4Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada and 5Department of Health Policy, Management 
and Evaluation, University of Toronto,   Toronto, Ontario, Canada
Email: Shaun Treweek* - streweek@mac.com; Merrick Zwarenstein - merrick.zwarenstein@ices.on.ca
* Corresponding author    
Abstract
Randomised controlled trials are the best research design for decisions about the effect of different
interventions but randomisation does not, of itself, promote the applicability of a trial's results to
situations other than the precise one in which the trial was done. While methodologists and trialists
have rightly paid great attention to internal validity, much less has been given to applicability.
This narrative review is aimed at those planning to conduct trials, and those aiming to use the
information in them. It is intended to help the former group make their trials more widely useful
and to help the latter group make more informed decisions about the wider use of existing trials.
We review the differences between the design of most randomised trials (which have an
explanatory attitude) and the design of trials more able to inform decision making (which have a
pragmatic attitude) and discuss approaches used to assert applicability of trial results.
If we want evidence from trials to be used in clinical practice and policy, trialists should make every
effort to make their trial widely applicable, which means that more trials should be pragmatic in
attitude.
Introduction
The statistical experiment, or, as we know it in medicine,
the randomised controlled trial (RCT) is among the more
beautiful intersections between man and mathematics.
RCTs minimise the risk of bias (threats to internal valid-
ity), particularly selection bias [1,2] and are thus the best
research design for decisions about the effect of different
interventions, be they treatments, therapies or delivery
methods and policies. But, as Cochrane noted, there is a
snag: randomisation does not, of itself, promote external
validity; that is, the applicability of a trial's results to situ-
ations other than the precise one in which the trial was
done [3]. It is thus possible for a trial to be free of bias but
be of no relevance beyond the immediate setting,
patients, and practitioners among whom it was con-
ducted. This question of applicability is central to those
who have to choose between therapies for groups of
patients (policymakers), for their own patients (clini-
cians) or for themselves (patients and families). How
likely is it, these decision makers may ask, that this treat-
ment (apparently successful in this trial or review) will
achieve important benefits in my context, administered to
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me by my clinicians, by me to my patients, or by clinicians
to patients in my organisation? In other words, 'Are these
published findings applicable to my decision?'.
This narrative review is aimed at those planning to con-
duct trials, and those aiming to use the information in
them. It is intended to help the former group make their
trials more widely useful and to help the latter group
make more informed decisions about the wider use of
existing trials. We review the differences between the
design of most RCTs and the design of trials more able to
inform decision making, discuss some approaches used to
assert applicability and end by proposing:
1. That applicability should be explicitly considered by tri-
alists as they plan their trial, and by decision makers when
gathering evidence to guide decisions.
2. That trialists explicitly design their trials to produce
results that are more widely applicable than is the case at
present.
3. That trialists can and should report their trials in ways
that make it easier for others to make judgements about
their applicability.
4. That decision makers seek trials with a pragmatic atti-
tude to inform choices that directly affect clinical care,
health services delivery and health policies.
5. That researchers conduct, and research funders fund,
empirical research to understand the major determinants
of applicability.
Explanatory and pragmatic attitudes to trials
Two French statisticians, Schwartz and Lellouch, were
acutely aware over 40 years ago of the limited applicabil-
ity of many trial results beyond the artificial, 'laboratory'
environment of the trial [4]. They proposed a distinction
between trials aimed at confirming a physiological
hypothesis, precisely specified as a causal relationship
between administration of an intervention and some
physiological outcome (which they called 'explanatory')
and the entirely different group of trials aimed at inform-
ing a clinical, health service or policy decision, where this
decision involves the choice between two or more inter-
ventions (called 'pragmatic').
While explanatory trials have an important role in provid-
ing knowledge concerning the effects of precisely defined
interventions applied to select groups under optimal con-
ditions, healthcare interventions are seldom given under
such circumstances [5,6]. Moreover, inadequate consider-
ation of applicability is the most frequent criticism by cli-
nicians of randomised trials, systematic reviews and
guidelines [7,8]. For example, a clinician considering a
treatment for secondary prevention of stroke might read
results from the Heart Outcomes Prevention Evaluation
(HOPE) trial and wonder what to make of the long list of
exclusion criteria, the exclusion of nearly 1 in 10 of the
remaining patients because of non-adherence, side-effects
or withdrawal of consent in the pretrial run-in phase, and
the use of placebo as comparator rather than aspirin [9].
Calls for more trials with wide applicability have come
both from those interested in improved treatment for clin-
ical problems [10-12] and those interested in health pol-
icy [13,14].
Schwartz and Lellouch characterised pragmatism as an
attitude to trial design rather than a characteristic of the
trial itself. Although some authors appear to suggest that
a trial is either explanatory or pragmatic [15], there is a
continuum rather than a dichotomy between explanatory
and pragmatic trials with the pragmatic attitude explicitly
favouring design choices that maximise applicability of
the trial's results to usual care settings. As Schwartz and
Lellouch wrote:
' [m]ost trials done hitherto have adopted the explanatory
approach without question; the pragmatic approach
would often have been more justifiable'.
As summarised in [16-18], we are aware of only a single
study that has attempted to identify pragmatic trials (iden-
tified using: MeSH term 'clinical trial', keyword 'prag-
matic' and authors' judgement that identified studies
described clinical trials with a pragmatic attitude) and it
found just 95 published between 1976 and 2002 [19].
Since PubMed identifies over 168,000 RCTs for that
period, trials with a pragmatic attitude are clearly the
exception even if we make allowances for Vallvé et al.'s
rather narrow search [19]. This is at least in part due to the
requirements of regulatory agencies, especially the US
Food and Drug Administration (FDA) [16-18]. Although
the FDA offers little guidance on the design of trials, what
guidance there is argues against trials with a pragmatic
attitude: ' [T]here are numerous ways of conducting a
study that can obscure differences between treatments,
such as poor diagnostic criteria, poor methods of meas-
urement, poor compliance, medication errors, or poor
training of observers. As a general statement, carelessness
of all kinds will tend to obscure differences between treat-
ments. Where the objective of a study is to show a differ-
ence, investigators have powerful stimuli toward assuring
study excellence' [20]. The FDA equates explanatory
design choices with study excellence, thereby favouring
trials that lack the attributes needed to support decisions
about the applicability of a treatment or therapy to usual
practice [16-18]. Conversely, the clinical, policy and fund-
ing decision makers who are expected to use these trialsTrials 2009, 10:37 http://www.trialsjournal.com/content/10/1/37
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for real world funding and clinical decision making are
not convinced of their relevance and applicability to their
patients or settings [14].
How might a trial with a pragmatic attitude be more help-
ful to policymakers, clinicians and patients than an
explanatory trial? Below we recount two trials demon-
strating some of the problems created when trials are not
widely applicable.
Consider the Vioxx Gastrointestinal Outcomes Research
(VIGOR) trial, which assessed whether rofecoxib (Vioxx)
was associated with a lower incidence of upper gastroin-
testinal events than the non-selective non-steroidal anti-
inflammatory drug (NSAID) naproxen among patients
with rheumatoid arthritis [21]. The patients with rheuma-
toid arthritis included in this trial were highly selected; in
particular, those with recent cardiovascular events and
those taking aspirin were excluded. Patients were followed
up for an average of 8 months. Despite VIGOR showing
an increased risk of cardiovascular events in patients tak-
ing rofecoxib, this was attributed to the protective effect of
naproxen. It was not until a later trial of rofecoxib with
longer follow-up, the Adenomatous Polyp Prevention on
Vioxx (APPROVe) trial, modified its protocol to include
patients at higher baseline risk for a cardiovascular event
to be enrolled that the increased cardiovascular risk
became undeniable and rofecoxib was withdrawn from
the market [22]. Had VIGOR taken a more pragmatic
approach to participant selection and follow-up, it is
likely that the balance of benefit and harm for refecoxib
would have been evaluated differently, and far fewer peo-
ple would have been exposed to these risks.
The National Institute of Neurological Disorders and
Stroke (NINDS) trial found a benefit for thrombolytic
therapy when used with acute ischemic stroke patients
who have had symptoms for less than 3 h [23]. However,
in clinical practice, a minority of patients present within 3
h. Moreover, the recruitment protocol of the NINDS trial
required 50% of participants to have presented within 1.5
h, a group that is almost non-existent in practice [24].
These design features practically guaranteed that the result
of this trial would have poor applicability to the patients
more typically seen in clinical practice, necessitating trials
with wider inclusion criteria such as International Stroke
Trial 3 (IST-3) [25].
The problem of applicability is enlarged when we con-
sider guidelines, where many trials contribute to each rec-
ommendation. Travers et al. looked at the extent to which
community-based asthma and chronic obstructive pul-
monary disease (COPD) patients, respectively, would be
eligible for the 17 major trials cited in the Global Initiative
for Asthma (GINA) guidelines [26] or the 18 major trials
cited in the Global Initiative for Chronic Obstructive Lung
Disease (GOLD) guidelines [27]. Of the 749 individuals
responding to their survey, a median 4% with current
asthma (range 0% to 36%) and a median 6% (range 0%
to 43%) with current asthma on treatment met the eligi-
bility criteria for the GINA trials. For the GOLD guide-
lines, a median 5% (range 0% to 20%) with COPD and a
median 5% (range 0% to 9%) of those with COPD receiv-
ing treatment met inclusion criteria. Such restrictive entry
criteria make it very difficult for clinicians to use such
guidelines.
Using narrow inclusion criteria for a trial may be appro-
priate if: (a) there is evidence to support a strong relation-
ship between the selection criteria and treatment
response, (b) the criteria used for selection are reasonably
common among the typical patient population, both for
reasons of trial feasibility and for reasons of population
impact, and (c) a typical clinician caring for patients with
this condition could easily use these criteria to select
patients. In the absence of selection criteria with these
traits, the best estimate of treatment effect under real
world conditions, is, for any individual patient, the aver-
age treatment effect of an intervention on an unselected
group of patients with that condition, rather than the
treatment effect found in a small and narrow subgroup,
defined by multiple exclusion criteria. There are three rea-
sons for this counterintuitive conclusion. Firstly, any sin-
gle patient to whom we wish to apply the results of a trial
is far more likely to be found within the ranks of unse-
lected patients included in a pragmatic trial, than in the
highly selected patients of an explanatory trial. Secondly,
even though we have substantial epidemiological knowl-
edge about the prognostic factors for disease incidence
and outcomes in a population, we have far less knowledge
of the clinical and biological characteristics of patients,
which determine their treatment response. Thirdly, even
in those instances where we know a prognostic factor
which influences treatment response, few such factors are
overwhelmingly powerful, and sufficiently common to be
relevant on a large scale. For those few that are, it is rare to
find any which can be implemented in a programmatic
fashion once the intervention is proven for the group with
that factor.
Our point is not that there should be no explanatory tri-
als. One can argue that most first trials of a healthcare
intervention with an obvious and well understood mech-
anism of action should be small, rapidly conducted pilot
trials towards the explanatory end of the explanatory-
pragmatic continuum [28]. If this trial rules out a benefit
in a select group of patients, treated under ideal condi-
tions, who are thought, based on mechanistic reasoning,
to be most likely to benefit then there is no need for more
trials. But if the intervention does show a benefit it is stillTrials 2009, 10:37 http://www.trialsjournal.com/content/10/1/37
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unclear whether it works in the real world, which is why a
trial at the pragmatic end of the explanatory-pragmatic
continuum is then needed. This trial should involve par-
ticipants (both clinicians and patients) who are like those
for whom the intervention is relevant in the real, messy
world of clinical practice [18]. This pragmatic trial should
use the current accepted treatment as the comparator,
require no more financial or staff resources than are cur-
rently available in the type of practice or clinic expected to
deliver the new intervention, and the trial should measure
an outcome that is of immediate importance to both
patients and clinicians [18].
If an intervention is not well understood, or if the inter-
vention has been used in another indication, and the
mechanism by which it will provide benefit on a new
indication is not clear, then a more pragmatic trial is the
place to start. This can be followed, if subgroup analysis
reveals startlingly different results in some participant
groups, by a trial in which all participants lie within the
group who obtained unique benefit.
Designing pragmatism
There is broad agreement on the type of design decisions
that make a trial explanatory or pragmatic in attitude
[4,11,14,15,28-32], and Table 1 shows some key differ-
ences. Trialists who describe their trials as pragmatic have
made design decisions that they believe will make it more
likely their trial will achieve its purpose of informing real
world decision about which among the alternative treat-
ments to choose [33-37].
But how does a trialist with this goal in mind know that
his or her trial does indeed have the right design for its
purpose? There are at least two tools available to help tri-
alists and others judge where on the explanatory-prag-
matic continuum a trial is best placed though they have
somewhat different aims. The first, developed by Gartleh-
ner et al. [30] characterised trials as efficacy (explanatory)
or effectiveness (pragmatic) trials, and was designed to
classify trials for systematic review and to help clinicians
judge the applicability of trial results. The tool has seven
criteria considered relevant to judgements as to where a
trial is placed on the efficacy-effectiveness continuum.
These include considerations of the trial setting, its inclu-
sion criteria, the choice of health outcome and the length
of follow-up. The authors asked the directors of 12 evi-
dence-based practice centres (centres that conduct system-
atic reviews) in the USA and Canada to nominate 6 trials
each: 4 effectiveness studies and 2 efficacy trials. Then, 2
independent raters applied the tool's 7 criteria to the 24
trials that met the study's eligibility criteria. A score of 6
criteria met gave the best balance between sensitivity and
specificity for identifying effectiveness trials; at this thresh-
old the tool identified 13 of 18 trials judged to be effec-
tiveness trials by the 12 directors. Used in this
dichotomous fashion, however, the tool does tend to rein-
force the misconception that a trial is either explanatory or
pragmatic, rather than acknowledging that there is a con-
tinuum. It has the added problem that one criterion is
whether or not the setting of the trial is in primary care,
implying that a trial conducted in, say, a referral hospital
cannot be oriented towards asking questions of real world
effectiveness, even though many patients are treated in
such settings.
A more recent tool, the pragmatic-explanatory continuum
indicator summary (PRECIS) [29], (figure 1) is intended
to be used by trialists designing a trial to assess the degree
to which their design decisions align with the trial's stated
purpose. This tool has 10 dimensions based on trial
design decisions (for example, participant and practi-
tioner expertise, flexibility with which the intervention
can be delivered and choice of comparator), and presents
these on a graphical, 10-spoked 'wheel'. A highly prag-
matic trial is out at the rim, while explanatory trials are
nearer the hub. Table 1 compares the highly pragmatic
Directly Observed Treatment (DOT) trial [38] with the
highly explanatory North American Symptomatic Carotid
Endarterectomy Trial (NASCET) [39]. The advantage of
Table 1: Key differences between trials with explanatory and pragmatic attitudes (from Zwarenstein et al. [48]).
Explanatory attitude Pragmatic attitude
Question Efficacy: can the intervention work? Effectiveness: does the intervention work when used 
in normal practice?
Setting Well resourced, 'ideal' setting Normal practice
Participants Highly selected; poorly adherent participants and those with 
conditions which might dilute the effect are often excluded
Little or no selection beyond the clinical indication of 
interest
Intervention Strictly enforced and adherence is monitored closely Applied flexibly as it would be in normal practice
Outcomes Often short-term surrogates, or process measures Directly relevant to participants, funders, 
communities and healthcare practitioners
Relevance to practice Indirect: little effort is made to match the design of the trial to the 
decision making needs of those in the usual setting in which the 
intervention will be implemented
Direct: the trial is designed to meet the needs of 
those making decisions about treatment options in 
the setting in which the intervention will be 
implementedTrials 2009, 10:37 http://www.trialsjournal.com/content/10/1/37
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this graph is that it quickly highlights inconsistencies in
how the 10 dimensions will be managed in a trial. For
example, if the DOT trial had intensely monitored com-
pliance and intervened when it faltered, a single glance at
the wheel would have immediately identified this incon-
sistency with the trial's otherwise pragmatic attitude. This
allows trialists to make adjustments, if possible and
appropriate, to the design to obtain greater consistency
with their trial's purpose.
Describing context
While these tools do allow a trialist to assess the likely
impact of his or her design decisions on the trial's ability
to achieve its purpose, they do not address an important
observation made by Karanicolas et al. that how pragmatic
a trial is depends on perspective and context [40]. There is
disagreement as to which of perspective and context is the
more important [40-43], although both are clearly rele-
vant to someone trying to interpret a trial result. However,
while perspective is a feature of the individual reading the
trial report and hard for trialists to predict, context (the
distinctive features of a trial's setting, participants, clini-
cians and other staff) is a feature of the trial itself and
should be within the capabilities of trialists to describe.
We would argue, therefore, that trialists should not worry
about trying to guess the various perspectives of those
making decisions but should instead do all they can to
describe the context of their trial.
Two examples will help to illustrate this point. In a Dutch
pragmatic trial comparing web-based self-help for prob-
lem drinking with a six-page, web-based psychoeduca-
tional brochure on alcohol [44], one of the inclusion
criteria for the trial was that participants must have inter-
net access. While this might not be considered a restrictive
criterion in the Netherlands, where internet penetration
in 2007 was 88% [45], this would not be the case in, say,
Poland, where internet penetration is just under 30%
[46]. From the perspective of a clinician or policymaker in
Poland, one could imagine that a trial conducted in the
Dutch context is more explanatory, given the limited pen-
etration of the internet in Poland. Trialists based in the
Netherlands cannot be expected to know the perspectives
of decision makers in Poland but they can be expected to
recognise that an internet penetration of around 88% is
part of the context of their trial and report it, which was
not performed in this example [44]. Another example is a
pragmatic trial performed in Quebec, Canada, which
compared a pharmacist-managed anticoagulation service
with usual care delivered by general practitioners [47].
Although these trialists found that care was similar for
both groups, they also found that pharmacist-managed
care was more expensive. However, as the authors report,
this is context-specific because the comparator care pro-
vided by physicians was performed through telephone
consultation, for which physicians receive no monetary
compensation in Quebec. Without this contextual infor-
PRECIS diagrams (based on Thorpe et al [29]) Figure 1
PRECIS diagrams (based on Thorpe et al [29]).
PRECIS summary of the North American Symptomatic Carotid 
Endarterectomy Trial (NASCET) of carotid endarterectomy for 
symptomatic patients with high-grade carotid stenosis36.
PRECIS summary of a randomised controlled trial of self-
supervised and directly observed treatment of tubercolosis 
(DOT)35Trials 2009, 10:37 http://www.trialsjournal.com/content/10/1/37
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mation some readers may conclude that the intervention
is not applicable to their contexts; with it they may see an
opportunity for improving the delivery of care.
Decisions about applicability depend on readers being
able to assess the feasibility of the intervention in their
own context [48]. However, understanding what com-
prises the intervention (and often the comparator) is not
always a simple matter of reading the trial report [49].
Detailed reporting of the content of interventions, espe-
cially complex, non-pharmacological ones, is often poor
[49-51]. For example, 41 of 80 published descriptions of
studies selected for abstraction by the journal Evidence-
Based Medicine from October 2005 to October 2006 failed
to adequately describe all elements of the intervention
[49]. A study of 47 trials involving nurses found that infor-
mation about the nurses delivering interventions (for
example, qualifications, experience, training) was often
lacking [52]. This is important contextual information
without which it is extremely difficult for readers to make
informed judgements about applicability; indeed, it may
be impossible.
The recent Consolidated Standards of Reporting Trials
(CONSORT) Statement extension for the reporting of
pragmatic trials should go some way to improving the
reporting of contextual information [48], especially the
recommendation for reporting information about the
participants and on applicability (or generalisabilty) of
the trial findings. Initiatives such as the Workgroup for
Intervention Development and Evaluation Research
(WIDER) [53], the CONSORT extension for non-pharma-
cological treatments [51] and the Standards for QUality
Improvement Reporting Excellence (SQUIRE) Statement
[54] are likely to help others to both judge the applicabil-
ity of an intervention to their own setting and implement
it should they choose to. A trial report with a poor descrip-
tion of the intervention is effectively rendered useless
because implementing it elsewhere becomes a matter of
guesswork. Readers need to know 'who, what, when and
where' [49].
Assessing applicability
For pragmatic trials, where the intention is to interfere as
little as possible with the usual process of care, under-
standing context is essential. But how are its effects meas-
ured? Despite its importance, there is little work exploring
how context might influence the results of a trial, or the
feasibility of widespread implementation.
The Normalisation Process Model [55-58] may be able to
help. The model was developed to guide the design of
evaluations of the implementation of complex interven-
tions but applies equally to the study of simple interven-
tions that have complex requirements of the healthcare
system needed to deliver them. It may also be adapted to
guide the investigation of the feasibility of interventions
in advance of their implementation, as it assists in the sys-
tematic and comprehensive mapping of the human,
organisational and resource changes that an intervention
will require. Some interventions can only be imple-
mented with major structural or organisational changes to
healthcare delivery; trials evaluating these interventions
might be called 'aspirational'. The Normalisation Process
Model could help to identify such interventions and allow
trialists and others to better judge whether the required
changes are feasible on a wide scale and whether the likely
benefit of the intervention justifies making them. Docu-
ments linked to trial reports could provide empirical data,
both quantitative and qualitative, on the features of
health care providers, patients or working practices which
influenced the observed results, putting judgements about
the feasibility of interventions (and hence applicability of
the trial's results) on a firmer basis.
The applicability of trial results can also be estimated
through statistical modelling. Here the influence of one or
more features of a trial, such as the selection of partici-
pants, is investigated using statistical techniques to see
how sensitive the trial result is to the feature or features
being varied. For example, Greenhouse et al. have devel-
oped techniques for making what they call generalisabilty
judgements, which are based on comparisons between
RCT participants and individuals included in large sur-
veys, databases and epidemiologic studies that are known
to be representative of the population of interest [59].
These authors were interested in a question familiar to
users of trials with a pragmatic attitude: how similar are
the trial's participants to those of the target population in
general? This is clearly relevant to applicability. Green-
house et al. compared the demographic profiles of youths
included in trials of antidepressants with the profiles of
depressed adolescents contained in a national database,
the Youth Risk Behaviour Survey. Although both the trial
and survey populations were found to be similar for most
demographic characteristics, the rate of suicidal ideation
and suicidal behaviours (the trial's primary outcomes) in
the trial participants was found to be about half the
adjusted rate among depressed adolescents in the USA as
estimated from the national database (3.6% vs 7.1%)
[59]. This difference appeared to be due to trials excluding
adolescents considered to be at high risk of suicide.
Although one might reach the same general conclusion of
limited applicability after using, say, the PRECIS tool [29],
the technique used by Greenhouse et al. provides a quan-
titative estimate of applicability, at least with regard to
participant selection. Other aspects of applicability have
also been considered using quantitative methods.
Yamaguchi and Ohashi used a proportional hazards
model to investigate the influence of treatment-by-centreTrials 2009, 10:37 http://www.trialsjournal.com/content/10/1/37
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and baseline risk on the trial result in a multicentre super-
ficial bladder cancer trial [60]. Yamaguchi and Ohashi
found that although there was some variation between
centres, especially in the baseline risk, this made little dif-
ference to the estimate of treatment effect. While we
shouldn't overstate the predictive power of modelling on
the benefits of an intervention applied outside the trial's
original context, it does have a role to play.
Conclusion
An internally valid trial that has poor applicability, or is
reported in such a way that it is difficult or impossible for
others to make judgements about its applicability, is a lost
opportunity to influence clinical practice and healthcare
delivery. It is worth repeating a line from Rothwell's 2005
Lancet paper: 'Lack of consideration of external validity is
the most frequent criticism by clinicians of RCTs, system-
atic reviews, and guidelines' [8]. An increase in the
number of well-designed trials with a pragmatic attitude is
surely needed. Perhaps the FDA and other regulatory
authorities might also consider revisiting the gap in their
regulations on the design of trials whose goal is to support
decision making. The FDA's dismissal of much of the real-
ity of real-life clinical practice as carelessness to be
avoided in a trial does not help a trialist who wants to
design a trial that can be used by policymakers and clini-
cians to decide which of several competing treatments
they should be using in the unkempt world of usual prac-
tice.
Some trials aim to provide data on whether an interven-
tion can be effective under optimal conditions; these trials
have an explanatory attitude. Others aim to show that an
intervention is effective in real and far from ideal condi-
tions; these trials have a pragmatic attitude. Both attitudes
have their place. However, we believe that:
1. More trials should have a pragmatic attitude.
2. Trialists should give as much care and attention to
issues of applicability as they already do to issues of inter-
nal validity.
So, what should trialists do to improve the applicability of
their trials? Trialists should routinely ask themselves at the
design stage of their trial 'Who are the people I expect to
use the results of my trial and what can I do to make sure
that these people will not be forced to dismiss my trial as
irrelevant to them, their patients, or their healthcare sys-
tems?' Rothwell gives a good list of issues that affect appli-
cability [8], and Table 1's 'Pragmatic attitude' column
gives pointers to design issue that can increase applicabil-
ity, as does the CONSORT extension for pragmatic trials
[48]. The PRECIS tool [29] and that by Gertlehner et al.
[30] can help trialists to match design to purpose. While
there is some evidence suggesting factors that have influ-
enced applicability, there is not enough empirical study of
this question, and we are in need of a body of work similar
to that performed over the past decades on internal valid-
ity. We would suggest that attention is given to the follow-
ing:
1. Summarising existing evidence on the relevance of trials
to decision making within a trial's own context and, if
available, on relevance to other contexts.
2. Developing a methodology for identifying contextual
factors of importance and estimating their influence on
applicability.
3. Developing standards for describing and reporting con-
textual information.
Wells provides a list of research recommendations linked
to trials of complex interventions, which is also relevant
[61].
Users of trial reports need to make judgements about the
applicability of the results to their own context, a task to
which those designing the trial often give insufficient
thought. If we want evidence from trials to be used in clin-
ical practice (and we do), trialists should make every effort
to make their trial widely applicable, which means that
more trials should be pragmatic in attitude [16-18]. Trial-
ists should not give policymakers, clinicians and patients
reason to ignore research evidence.
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